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Abstract 
Background: LILRA3 is an immunostimulatory molecule which can conditionally induce the proliferation of cyto-
toxic cells. LILRA3 has a deletion genotype which is associated with multiple immune disorders. In this study, we 
wanted to analyze the regulation of LILRA3 and its significance in the context of HIV infection.
Results: We analyzed a panel of TLR agonists and found that ssRNA40, a TLR8 agonist, is a potent inducer of LILRA3 
in healthy individuals. However, this regulation is much diminished in HIV. Comparison of TLR8 to TLR4 induction of 
LILRA3 indicated that LPS induces less LILRA3 than ssRNA40 among healthy controls, but not HIV patients. Levels of 
LILRA3 induction correlated to virus load and CD4 counts in untreated patients. Recombinant LILRA3 can induce a 
host of proinflammatory genes which include IL-6 and IL-1α, as well as alter the expression of MHC and costimulatory 
molecules in monocytes and B-cells.
Conclusion: Our experiments point towards a beneficial role for LILRA3 in virus infections, especially in ssRNA viruses, 
like HIV, that engage TLR8. However, the potentially beneficial role of LILRA3 is abrogated during a HIV infection. We 
believe that more work has to be done to study the role of LILRA3 in infectious diseases and that there is a potential 
for exploring the use of LILRA3 in the treatment of virus infections.
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Background
Extensive work has been done to functionally character-
ize members of the leukocyte immunoglobulin like recep-
tor (LILR) family [1–11]. In comparison, the function of 
leukocyte immunoglobulin like receptor A3 (LILRA3; 
ILT6; CD85e) has been less well characterized. LILRA3 
is a 70 kDa highly glycosylated protein secreted by mono-
cytes. The differentiation of monocytes into osteoclasts 
and dendritic cells has been shown to upregulate LILRA3 
[12, 13]. It is the only member of the LILR family that 
exists constitutively as a soluble protein due to a lack of 
a transmembrane domain and cytoplasmic tail. LILRA3 
binds to HLA-G and classical HLAs with a much lower 
affinity than LILRB1 and LILRB2 [14], although it seems 
to bind to free heavy chain forms of HLA-C with higher 
affinity [15].
Around 30 % of healthy Caucasians carry the LILRA3 
deletion of 6,7  Kb which includes nearly the complete 
coding sequence [8, 16]. The homozygous deletion is 
found in 3  % of the healthy Caucasian population and 
confers susceptibility to some autoimmune diseases [17–
19], HIV-infection (in revision), and B cell non-hodgkin 
lymphoma [20].
Other members of the LILR family were demonstrated 
to play important roles in HIV infection [21]. Myeloid 
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dendritic cells in elite controllers, who spontaneously 
maintain low viremia, have a selective upregulation of 
LILRB1 and LILRB3, whereas patients with a progres-
sive infection showed a downregulation of LILRA2 and 
upregulation of LILRB2 [22].
As we have shown in a previous report, LILRA3 is an 
immunostimulatory molecule that specifically induces 
the proliferation of CD8 T-cells and NK-cells in the pres-
ence of allogeneic stimulation, as well as the produc-
tion of pro-inflammatory cytokines [20]. Based on these 
properties, we suspect that LILRA3 could be involved 
in immune responses against viruses. However, nothing 
is known about the processes upstream of LILRA3 and 
their regulation.
Pattern recognition receptors (PRRs) are widely 
expressed on a variety of immune sensing cells. They rec-
ognize pathogen associated molecular patterns to initiate 
the innate immune response and direct adaptive immu-
nity [23, 24]. The best characterized PRRs are the toll-like 
receptors (TLR). Among the 10 members which sense 
a variety of infection types, those associated with virus 
infections are intracellular TLR3 (dsRNA), -7, -8 (both 
ssRNA) and -9 (unmethylated CpG DNA).
We used TLR-agonists as surrogates for whether 
virus infections could induce expression of LILRA3. We 
wanted to determine which TLR agonist could regulate 
LILRA3 expression and showed that ssRNA40, a TLR8 
agonist, is a most prominent regulator of LILRA3. Since 
HIV is an ssRNA virus which has been documented to 
induce aberrant TLR responses in hosts [25, 26], we ana-
lyzed the TLR8 regulation of LILRA3 expression in the 
context of HIV infection.
Results
TLR‑8 induces LILRA3 expression in CD14+ monocytes
In preliminary experiments, we subjected PBMCs from 
four donors to a panel of TLR agonist. Of the nine TLR 
agonists tested, a consistent immune response among 
the four donors, measured using IL6 expression, was 
only observed for Pam3Csk, heat-killed Listeria monocy-
togenes, LPS, flagellin, FSL-1 and ssRNA40. Three of the 
four donors had a substantial upregulation of LILRA3 to 
TLR8 agonist ssRNA40 (Fig. 1a), but we did not observe 
any obvious pattern of upregulation in LILRB1 and 
LILRA1 expression (Additional file 1: Figure S1). In order 
to confirm that TLR8 stimulation significantly upregu-
lates LILRA3, we expanded the cohort using ssRNA40 
stimulation, with ssRNA41 (similar to ssRNA40, but with 
uridine replaced with adenosine) as a control. Whereas 
ssRNA40 significantly upregulated the expression of 
LILRA3, ssRNA41 did not (Fig.  1b). LILRA3 could be 
detected in the supernatant of ssRNA40 stimulated 
LILRA3 positive PBMCs, but not in the negative controls 
and in the LILRA3−/− donor, even though both donors 
were positively activated by ssRNA40 to secrete IL6 
(Fig. 1c).
We determined monocytes to be the major producer 
of LILRA3 under ssRNA40 stimulation, as LILRA3 
mRNA was detected only in CD14+ monocytes after 
22-h ssRNA40 stimulation in PBMCs. In all three donors 
tested, almost all of the LILRA3 expression occurred 
in CD14+ monocytes, with two of the three donors 
expressing higher LILRA3 under ssRNA40 stimulation 
compared to LPS (Fig. 1d).
LILRA3 is upregulated after other proinflammatory 
cytokines
In order to determine the time point at which LILRA3 
expression is the highest, we performed expression kinet-
ics of LILRA3 using ssRNA40 stimulation of PBMCs. We 
also looked at the expression of other cytokines major 
cytokines as a comparison. Whereas the expression 
of the other cytokines tested peaked early at 4  h after 
ssRNA40 stimulation, LILRA3 expression only gradu-
ally increased to peak at 24 h, after which its expression 
declined (Fig. 2a). In order to test of other cytokines were 
responsible for the expression, we neutralized IL-1R, 
TNF, IL-6R and IFN-γ with their respective neutraliza-
tion antibodies (Anakinra, Certolizumab, Tocilizumab 
and IFN-γ neutralization antibody) to see if they had any 
effect on LILRA3 expression. No appreciable difference 
in ssRNA40-induced LILRA3 expression was observed 
even though expression of IL-6 was decreased in the 
presence of Anakinra and Certolizumab and increased 
in the presence of IFN-γ neutralization (Fig. 2b). In sum-
mary, LILRA3 expression by TLR-8 stimulation peaks 
at 24 h and is independent from the expression of other 
immune relevant cytokines.
TLR8 regulation of LILRA3 is abrogated in HIV infection
We performed real time PCR for LILRA3 induction 
by 24-h incubation with ssRNA40 in genotyped HIV 
untreated patients, treated patients and healthy con-
trols. Only samples of donors with at least one copy of 
the LILRA3 gene were analysed. Since monocytes are 
the major producers of LILRA3 and the percentages of 
monocytes could vary widely between persons, we per-
formed the stimulation on isolated monocytes so that 
the results would not influenced by monocytic counts. 
Intra-group Mann–Whitney test between unstimulated 
control and ssRNA40 stimulation revealed that all three 
groups had a significant upregulation of LILRA3 expres-
sion upon ssRNA40 stimulation (Fig.  3a). However, 
Kruskal–Wallis with Dunn’s multiple comparison test 
between the stimulated samples revealed that LILRA3 
expression in untreated HIV patients was significantly 
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reduced compared to healthy controls, which is partially 
restored in treated patients (Fig. 3a). Interestingly, segre-
gation of the patient and control groups into LILRA3+/+ 
and LILRA3+/− revealed higher LILRA3 expression 
among the LILRA3+/+ in healthy controls and HIV 
treated patients, although it was only significant among 
Fig. 1 LILRA3 induction by TLRs. a Induction of LILRA3 and IL6 expression by a panel of TLR agonists. LILRA3 and IL6 expression was measured, 
using qPCR, as fold change to the unstimulated control from PBMCs stimulated for 24 h with Pam3CSK4 (P3C), heat killed Listeria monocytogenes 
(HKLM), polyinosinic-polycytidylic acid (Poly I:C) in high molecular weight (HMW) and low molecular weight (LMW) forms, lipopolysaccharide (LPS), 
flagellin, synthetic diacylated lipoprotein FSL-1, Imiquimod (R837), ssRNA40/LyoVec and CpG oligonucleotide ODN 2006. b Induction of LILRA3 by 
ssRNA40 on the transcriptional level. LILRA3 expression was measured as fold change to the unstimulated control from PBMCs stimulated for 24 h 
with uridine-rich HIV-derived ssRNA40, using ssRNA41 as control (n = 8). Wilcoxon matched-pairs signed rank test was used to compare the median 
between ssRNA41 and ssRNA40 stimulated LILRA3 expression. Scatter dot plot overlayed on bar graph displayed as median with interquartile range. 
c Induction of LILRA3 in PBMCS by ssRNA40 on the protein level. 30 × 106/mL PBMCs from LILRA3+/+ and LILRA3−/− donors were stimulated with 
5 μg/mL ssRNA40. 40 µL from each supernatant was loaded and Ponceau S staining was used as loading control. The membrane was blotted for 
LILRA3 and IL6, using recombinant LILRA3 as protein control. d Expression of ssRNA40-induced LILRA3 by monocytes. PBMCs stimulated overnight 
with ssRNA40 and LPS were purified for CD14+ monocytes using magnetic-activated cell sorting. The resulting CD14+ positive and depleted frac-
tions were analysed via qPCR for LILRA3 expression, normalized to RPLP0 and relatively quantified to calibrator cDNA (*p < 0.05; **p < 0.01)
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the healthy controls (Fig. 3b). Even among the LILRA3+/+ 
samples, the HIV-untreated group had significantly lower 
LILRA3 expression than the healthy group and HIV-
treated group.
HIV infection selectively abrogates ssRNA40, but not LPS, 
activation of LILRA3
As LPS seems to also induce LILRA3 (Fig.  1a), albeit 
more weakly, we compared if there were differences 
between the TLR8 and TLR4-mediated LILRA3 produc-
tion. We performed the same experiment as before, with 
a new stimulus LPS for each sample. The second cohort 
confirmed the trend seen in the first cohort, with HIV 
untreated patients expressing less ssRNA40-induced 
LILRA3 compared to the healthy controls (Fig. 4a). How-
ever, after LPS stimulation, no significant difference was 
observed between healthy controls and HIV patients. 
Analysis of TNF expression via ELISA did not show 
a significant difference between healthy controls and 
HIV patients after both ssRNA40 and LPS stimulation 
(Fig. 4a). Correlation of ssRNA40 versus LPS induction of 
LILRA3 expression gave striking differences. Among the 
healthy controls, there was a much higher expression of 
LILRA3 induced by ssRNA40 in comparison to LPS, with 
a slope of 1.69 using linear regression (Fig.  4b). How-
ever, this trend was reversed in HIV-untreated patients, 
with LILRA3 expression higher after LPS rather than 
ssRNA40 stimulation, with a much more gradual slope 
of 0.51. Treated patients gave an intermediate trend, with 
a slope of 0.79. Correlation analysis showed a statisti-
cally significant relationship between ssRNA40 and LPS 
induced LILRA3 expression for healthy donors and HIV-
untreated donors.
Both ssRNA40 and LPS‑induced LILRA3 expression 
correlates with viral load and CD4 counts
Since we believe that LILRA3 can be helpful in a virus 
infection due to its ability to induce proliferation in 
Fig. 2 Features of ssRNA40-induced LILRA3 expression. a Kinetics of LILRA3 expression was compared to other ssRNA40 inducible cytokines. PBMCs 
from two donors were stimulated with ssRNA40 or ssRNA41 and the RNA was harvested at various time points. qPCR for LILRA3, TNF, IFNb, IFNg, and 
IL1b expression, normalized to RPLP0 and relatively quantified to calibrator cDNA (pooled cDNA from 10. b Effect of cytokine inhibition on LILRA3 
expression. PBMCs from two donors were stimulated overnight with ssRNA40 together with neutralizing agents anakinra, certolizumab, tocilizumab 
and IFN-γ neutralizing antibodies and analysed for LILRA3 and IL6 expression by qPCR. Repeated measures ANOVA was used to calculate difference 
of ssRNA40+ neutralization to ssRNA40 alone and results displayed as mean ± SD
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cytotoxic cell subsets [20], we hypothesize that expres-
sion of LILRA3 could indicate better disease status of 
the patients, i.e. lower viral load, higher CD4 and CD8 
T-cell and NK-cell counts. We performed a one-tailed 
Spearman correlation analysis of both ssRNA40 and LPS-
induced LILRA3 expression with the abovementioned 
clinical parameters and observed that higher induction of 
LILRA3 was significantly correlated with lower viral load 
of HIV-untreated patients. Virus loads were not analysed 
for treated patients because they were almost uniformly 
below 20 virus copies/mL. LILRA3-induction correlated 
positively with CD4 T-cell count in untreated patients 
(Fig.  4c), but not for treated patients (Additional file  2: 
Figure S2).
Many immune activation genes are upregulated by LILRA3
To identify genes and pathways regulated by LILRA3, we 
analysed the gene expression signature induced by over-
night incubation of PBMCs with recombinant LILRA3. 
Analysis of the microarray data revealed that among the 
top 50 genes upregulated by LILRA3, there appears to 
be a dominance of genes involved in immune activation, 
the foremost of which are the acute phase inflammatory 
cytokines IL-6 and IL-1α (Additional file 3: Figure S3A). 
The list of genes downregulated by LILRA3 however, 
paints a rather mixed picture, with a sprinkle of immu-
noregulatory genes like TREM2, CXCL11 and proteins 
involved in metabolic processes (e.g. CD36 and FABP4) 
or with less well known functions (e.g. PLBD1, LGALS2). 
Using gene set enrichment analysis (GSEA), we discov-
ered a highly significant enrichment of several processes 
and pathways, among which chemotaxis, hematopoietic 
cell lineage pathways and genes involved in the patho-
genesis of the autoimmune disorder rheumatoid arthritis 
(RA) had the highest number of annotated genes upregu-
lated (Additional file 3: Figure S3B). Using realtime PCR, 
we confirmed the upregulation of IL6, IL1A and IL1B 
by LILRA3 (Fig.  5a). However, the consolidation of the 
results from the 4 different donors were confounded by 
the different optimum concentration of LILRA3 required 
Fig. 3 Analysis of ssRNA40-induced LILRA3 expression in HIV. a Monocytes of healthy donors, HIV-untreated and HIV-treated patients were enriched 
using the Rosettesep system and stimulated overnight with ssRNA40 and analysed using qPCR for LILRA3. Wilcoxon matched-pairs signed rank test 
was used to compare intra-group unstimulated and ssRNA40-stimulated LILRA3 expression. Kruskal–Wallis test was used to compare inter-group 
ssRNA40-stimulated LILRA3 expression. Results displayed as median with interquartile range. b The values for the ssRNA40-induced LILRA3 (without 
unstimulated controls) were segregated according to genotype (LILRA3+/+ and LILRA3+/−). Mann–Whitney test was used to compare intra-group 
LILRA3 expression. Kruskal–Wallis test was used to compare inter-group LILRA3 expression among LILRA3+/+ donors. Results displayed as median 
with interquartile range (*p < 0.05; **p < 0.01; ***p < 0.001)
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for stimulation for different donors, with donors 1 and 
4 needing at least 1000  ng/mL LILRA3, while donors 2 
and 3 requiring 500  ng/mL of LILRA3, beyond which 
the stimulation is abrogated. Purification from a mock-
transfected expression did not lead to an increase of IL6 
production like the purified LILRA3 (Additional file  4: 
Figure S4). LILRA3 did not have much of an effect on 
LILRA3 itself and on IL10 (Fig. 5a).
LILRA3 effects on the MHC and costimulatory molecules
Since LILRA3 binds to an undetermined ligand expressed 
on the surface of monocytes and B-lymphocytes [20, 27], 
Fig. 4 Relationship between ssRNA40 and LPS-induced LILRA3. a Monocytes of healthy donors, HIV-untreated and HIV-treated patients were 
enriched using the Rosettesep system and stimulated overnight with ssRNA40 and LPS. LILRA3 expression was analyzed using qPCR and TNF 
expression was analyzed using ELISA. Kruskal–Wallis test was used to compare inter-group ssRNA40-stimulated LILRA3 and TNF expression. Bar 
graph depicts median with interquartile range. b Correlation analysis of ssRNA40 versus LPS induced LILRA3 expression. Two-tailed spearman 
analysis was used to calculate correlation. Non-linear regression straight line robust fit was used to calculate the trend lines. c Relationship between 
ssRNA40/LPS induced LILRA3 expression and disease parameters in HIV-untreated patients. One-tailed Spearman analysis was used to calculate cor-
relation between LILRA3 expression and virus loads, CD4 and CD8 T-cell and NK-cell counts in HIV-untreated patients. Non-linear regression straight 
line robust fit was used to calculate the trend lines
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Fig. 5 LILRA3 stimulation of cytokines and antigen presenting cells. a qPCR of LILRA3 induced gene expression of LILRA3, IL-6, IL-1A, IL-1B and IL-10. 
Due to the different optimal concentrations of LILRA3 for various donors, the gene expression of all four donors were shown, with the correspond-
ing mean ± SD. b Effect of LILRA3 on the antigen presentation mechanism of monocytes and B-cells. PBMCs were stimulated with varying concen-
trations of LILRA3 for 48 h and analysed by flow cytometry for expression of CD80, CD86, HLA-DR and HLA-ABC on monocytes (CD14+CD33+) and 
B-cells (CD3+CD19+). On monocytes, upregulation of HLA-ABC and CD80 was observed, whereas CD86 was downregulated. On B-cells, there was a 
slight but significant upregulation of HLA-DR and CD86. 1-way ANOVA with repeated measures Dunett post test was used to compare to 0 ng/mL 
LILRA3 control. Results expressed as mean ± SD from six donors. (*p < 0.05; **p < 0.01; ***p < 0.001)
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we tested if there is a direct effect of LILRA3 binding in 
the regulation of the MHC and costimulatory molecules 
expression levels on these cells. On monocytes, incuba-
tion with LILRA3 selectively upregulated HLA class I and 
CD80 surface expression. Notably, CD86 was conversely 
downregulated, whereas there was no significant change 
in HLA class II expression (Fig. 5b). On B-cells, there was 
a selective upregulation of HLA class II and CD86. How-
ever, no significant difference in the expression levels of 
HLA class I and CD80 were detected.
Discussion
TLRs and LILRs are two families of receptors which are 
widely and distinctly expressed on immune cells. Other 
members of the LILR family of receptors have been 
implicated in the control of TLR activity to several dif-
ferent bacterial infections (reviewed in [28]). The LILRs 
have also been shown play a role in viral infections like 
HIV [29–31]. We showed that ssRNA40, a TLR8-agonist, 
is the most prominent regulator of LILRA3 expression 
among the TLRs, and that this was mainly mediated by 
the monocyte population. ssRNA40 is a uridine-rich sin-
gle stranded RNA sequence derived from the U5 region 
of HIV-1. Although ssRNA40 is an activating ligand for 
TLR7 in mice, in humans it has been shown to stimu-
late TLR8 responses in TLR8, but not TLR7, transfected 
HEK 293 cells [32]. Therefore, in our system, the ability 
of TLR7 and TLR9 to stimulate LILRA3 might be over-
looked as the cell populations that express these recep-
tors are underrepresented among the PBMCs. In human 
macrophages and dendritic cells, TLR3-ligand poly(I:C) 
has been shown to induce IFN-regulated genes, but not 
proinflammatory genes like TNF and IL6 [33], which 
might explain the missing IL6 response to poly(I:C) in 
our system.
Although LILRA3 expression peaks after 24 h, neutrali-
zation of IL-1R, TNF, IL-6R and interferon-γ did not lead 
to an appreciable change in LILRA3 (Fig.  2b), meaning 
that it is regulated independently of these cytokines. This 
could imply that LILRA3 expression is regulated directly 
by TLR8 signalling pathways or by other indirect path-
ways/cytokines, for example type I interferons, which 
is as yet unknown. This should be of interest for further 
investigation.
In HIV-untreated patients, we observed a significant 
abrogation of the monocytic TLR8-induced LILRA3 in 
comparison to the robust response of healthy controls, 
as well as a reconstitution of this response in treated 
patients (Fig.  3). It is crucial to note that in this study, 
we do not measure the constitutive LILRA3 expression 
in HIV patients, but rather the strength of the LILRA3 
response to TLR4 and TLR8 stimuli. This is more reflec-
tive of the immune status of the patients, rather than the 
constitutive expression due to viral loads. Nevertheless, 
the strength of the LILRA3 induction seems to be cor-
related with the viral load in untreated patients (Fig. 4c), 
suggesting a link between the strength of LILRA3 induc-
tion and the controlling of the infection. This would 
be consistent with previous studies showing that the 
strength of the TLR3, -7 and -8 responses are more 
robust among individuals who remain seronegative even 
after repeated sexual exposure to HIV [34], and that a 
mutant TLR8 allele which is more “functional” than the 
wild-type allele confers protection against HIV disease 
progression [35]. Considering that conventional dendritic 
cells also express TLR8 and are demonstrated play a role 
in control of HIV [36–38], it would be interesting to ana-
lyse their LILRA3 production in future experiments.
In order to assess whether the abrogation of LILRA3 
expression in HIV infection is TLR8-specific or a general 
dampening of the monocytic response, we looked at the 
LPS induction of LILRA3 expression via TLR4 in a second 
cohort. ssRNA40-induced LILRA3 correlated well with 
LPS-induced LILRA3 expression across the three groups, 
suggesting that they act on similar signalling pathways to 
induce LILRA3 (Fig. 5b). However, while TLR8 stimula-
tion gave a more robust LILRA3 response than TLR4 
stimulation in healthy controls, this trend is paradoxically 
skewed towards LPS in HIV patients, who might actually 
benefit more from the TLR8-ssRNA response rather than 
the TLR4-LPS response. It is tempting initially to attrib-
ute this to immune dysregulation in chronically HIV-1 
infected patients. However, the correlation between viral 
load and CD4 counts to LILRA3 expression that was pre-
sent under TLR8 stimulation was even more strongly 
correlated under TLR4 stimulation (Fig.  4c), suggesting 
that the strength of the LPS response is also a factor in 
containing HIV-1. It has been shown that sensitization 
of monocytes with HIV-1 or TLR8-ligands led to higher 
production of proinflammatory cytokines by subse-
quent stimulation by LPS [39]. One explanation could be 
that because the TLR8 response was exhausted in these 
chronically HIV-1 infected patients, another TLR(s) was 
used as a compensatory mechanism. When we analyzed 
TNF production after ssRNA40 stimulation, we did not 
observe any significant decrease in TNF expression in 
HIV untreated patients, suggesting other factors at play 
other than TLR-8 exhaustion.
At this stage, it is still unclear whether the robustness of 
the LILRA3 induction is a cause or an effect of improved 
viral control and we cannot rule out in our study that 
the stronger LILRA3 responses are due to a general 
healthier immune status of the patients with lower viral 
loads. However, in light of a recent study of the genetics 
of LILRA3 deletion in HIV patients by Ahrenstorf et al. 
(in revision), HIV patients have higher percentages of 
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LILRA3−/− donors and there is a faster progression of the 
infection with decreasing gene dosage. Taken together, 
there is evidence to suggest that LILRA3 is helpful in 
immune control of HIV.
LILRA3 expression level is confirmed to be depend-
ent on its gene-dosage, with LILRA3+/− donors express-
ing substantially less LILRA3 than LILRA3+/+ donors 
(Fig. 4b). The untreated HIV patients had such depressed 
levels of LILRA3 induction that both genotypes gave 
similar low levels of gene expression. This is in line with 
a previous study that revealed decreased LILRA3 expres-
sion in LILRA3+/− rheumatoid arthritis patients [40]. 
However, it is unclear whether this is the result of hap-
loinsufficiency or the deletion allele being dominant 
negative.
Previously, we have shown that LILRA3 can induce a 
host of proinflammatory cytokines. We also show now 
in this paper that LILRA3 can upregulate transcription 
of IL-6, IL-1A and IL-1B, but not LILRA3 itself and IL-
10. Previous studies have shown that IL6 have suppres-
sive effects on TNF production in vitro and in vivo [41, 
42]. As LILRA3 upregulates IL6, but not TNF, the IL6 
expression might have had repressive effects on TNF 
production, which could explain why Lee et al. [27] saw a 
repression of LPS-induced TNF by LILRA3. Interestingly, 
two out of the four donors we stimulated with LILRA3 
responded best at 1000  ng/mL, whereas the other 2 
responded at 500  ng/mL, but not at all at 1000  ng/mL 
(Fig.  5a). This means that LILRA3 activation is under 
very tight control, with different donors having different 
activation thresholds. The abrogation of its stimulatory 
effects at too high concentrations is most likely a mecha-
nism against overactivation.
LILRA3 can modulate the expression MHC and 
costimulatory molecules in monocytes and B-cells. 
Although monocytes are the major producers of LILRA3 
(Fig.  1d), the as yet unknown receptor for LILRA3 was 
found on monocytes and it exerts its immune modulat-
ing properties via the monocytes [20, 27]. One possibil-
ity is that this is a mechanism for infected monocytes to 
alert nearby monocytes about the presence of virus parti-
cles in the vicinity.
Gene set enrichment analysis showed that LILRA3 
regulates many genes involved in the pathology of RA 
(Additional file 3: Figure S3B). In the Han Chinese popu-
lation, the genetic presence of LILRA3 is associated with 
increased risk of rheumatoid arthritis [40].
Conclusion
Our data point towards a role of LILRA3 in virus immu-
nity. ssRNA40 is the most prominent inducer of LILRA3, 
which is produced by monocytes. Although HIV-1 
patients express significantly less LILRA3 in response 
to ssRNA40, the LPS-induced LILRA3 remained 
unchanged. We also revealed that both TLR8 and TLR4 
mediated LILRA3 expression can be correlated with viral 
loads and CD4 T-cell counts in untreated patients and 
that LILRA3 can upregulate proinflammatory cytokines, 
as well as induce changes MHC and costimulatory mol-
ecule expression monocytes and B-cells. Based on our 
findings, LILRA3 could potentially be exploited in the 
treatment of viral diseases like HIV.
Methods
PBMC and monocyte isolation and culture
PBMCs were isolated using density gradient centrifuga-
tion by layering blood onto Biocoll (Millipore) and cen-
trifugation at 1200×g for 20  min without brake. The 
resulting buffy layer was then washed twice with PBS 
before use in subsequent experiments. Monocyte enrich-
ment was performed using the RosetteSep™ Human 
Monocyte Enrichment Cocktail (Stemcell Technologies). 
Positive enrichment of CD14+ monocytes was performed 
using CD14 Magnetic Particles (Becton–Dickinson). 
Cells were counted using trypan blue staining on a Neu-
bauer hemocytometer and cultured at 37  °C with 5  % 
CO2, in RPMI 1640 supplemented with 100 U/mL peni-
cillin, 100  μg/mL streptomycin, 2  mM l-glutamine (all 
Biochrom), and 10 % AB serum.
RNA extraction and reverse transcription
Total RNA was extracted using Zymo Research Quick-
RNA Microprep (Zymo Research), utilizing RNase-
Free Dnase Set (Qiagen) for in-column genomic DNA 
removal. Reverse transcription was perform using 
High-Capacity cDNA Reverse Transcription Kit (Life 
Technologies).
Quantitative real‑time PCR
Expression levels of LILRA3, TNF, IL-1α, IL-1β, IFN-γ, 
IFN-β, IL-6 were normalized to the housekeeping gene 
60S acidic ribosomal protein P0 (RPLP0) and relatively 
quantified using the 2−ddCt method either to the unstim-
ulated control or to calibrator cDNA. Primer sequences 
are listed in Table  1. Calibrator cDNA was obtained 
from PBMCs ficoll purified from pooled blood of 10 
healthy donors. Real-time PCR was performed using the 
Maxima SYBR Green/ROX qPCR Master Mix (Thermo 
Scientific) on the ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems). The thermal cycling con-
ditions composed of an initial denaturation step of 95 °C 
for 10 min, followed by 40 cycles of denaturation (95 °C 
for 10 s), annealing and (60/57 °C for 20 s) and extension/
detection (72 °C for 40 s).
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Samples
Permission for the study was obtained from the Institu-
tional Review Board (IRB) of Hannover Medical School. 
Blood from HIV-1 chronically infected but untreated 
patients and HAART-treated patients with controlled 
viremia were obtained with written informed consent 
according to the Declaration of Helsinki from the HIV 
outpatient clinic of the Clinic for Immunology and 
Rheumatology, Hannover Medical School. Patient char-
acteristics are listed under Table  2. Blood of healthy 
controls were obtained anonymously from blood donors 
at the Institute of Transfusion Medicine, Hannover 
Medical School as well as from volunteers from the 
laboratory.
TLR‑agonist stimulation experiments
The Human TLR1-9 Agonist Kit (Invivogen) was used 
for the pilot study. 106/mL PBMCs were stimulated for 
24  h with 1  μg/mL Pam3CSK4 (P3C), 108 cells/mL heat 
killed Listeria monocytogenes (HKLM), 1  μg/mL polyi-
nosinic-polycytidylic acid (Poly I:C) in high molecular 
weight (HMW) and low molecular weight (LMW) forms, 
100 ng/mL lipopolysaccharide (LPS), 100 ng/mL flagellin, 
100  ng/mL synthetic diacylated lipoprotein FSL-1, 1  μg/
mL iniquimod, 1 μg/mL ssRNA40/LyoVec and 5 μM CpG 
oligonucleotide ODN 2006. For the kinetics, PBMC were 
stimulated with ssRNA40/Lyovec and ssRNA41 and har-
vested for real-time PCR analysis at various time points 
up to 48  h. For the rest of the stimulation experiments, 
PBMCs or monocytes were stimulated overnight for 
20–22 h with respective stimulants. In later samples, the 
supernatants from monocyte stimulation was analyzed 
for TNF production was analyzed using the TNF elisa 
kit (Biolegend). Anakinra (Sobi), Certolizumab (UCB) 
and Tocilizumab (Roche) were obtained as leftovers from 
clinical treatments and used to neutralize IL-1R, TNF and 
IL-6R respectively. Functional grade purified anti-human 
IFN gamma (eBioscience) was used to neutralize IFN-γ.
Table 1 Real-time PCR primers
(1) NCBI Primer Blast; (2) Primer Bank; (3) Sigma Aldrich KiqStart; (4) Primer Quest
Gene Sequence (5′–3′) Annealing temp. (°C) Length (bp) Source
RPLP0 Fwd TGCTTGATATCACAGAGGAAACTC 60/57 81 (1)
Rev CAATCTGCAGACAGACACTGG
LILRA3 Fwd AGGAGTGGGGACGTGACTT 60 202 (2)
Rev GGTCTGGCACGGATCTGTC
IFNB1 Fwd ATTCTGCATTACCTGAAGGCCA 60 141 (1)
Rev CCAGAGGCACAGGCTAGGA
IFNG Fwd TCGTTTTGGGTTCTCTTGGCT 60 243 (2)
Rev TCTCCACACTCTTTTGGATGCTC
TNF Fwd CTGGAAAGGACACCATGAGCA 60 237 (1)
Rev GGGCCAGAGGGCTGATTAGA
IL1A Fwd AGAGGAAGAAATCATCAAGC 57 122 (3)
Rev TTATACTTTGATTGAGGGCG
IL1B Fwd TCTTTGAAGCTGATGGCCCTAAA 60 188 (1)
Rev GAAGGTCTGTGGGCAGGGAA
IL6 Fwd GCAGAAAAAGGCAAAGAATC 60 178 (3)
Rev CTACATTTGCCGAAGAGC
LILRB1 Fwd TTCTATGACAGAGTCTCCCTCTCGGT 60 99 (4)
Rev AGTTTGCATCCATCCCTGTGACTG
LILRA1 Fwd ATCACAAAACAAGACTGCCTCACA 60 81 (1)
Rev AGGACCAAGCCAGCTATGCC









 Number 26 19 22
 Mean age (SD) 43.50 (12.15) 42.53 (12.87) 48.86 (10.00) >0.05
 Male:female 21:5 13:6 19:3 >0.05
Cohort 2
 Number 13 16 11
 Mean age (SD) 43.00 (14.49) 47.50 (12.70) 50.64 (12.92) >0.05
 Male:female 10:3 10:6 9:2 >0.05
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Western blot to detect LILRA3 secretion upon ssRNA40 
stimulation
Purified PBMCs from LILRA3 positive and deleted per-
sons were cultured in Optimem +0.5 % AB-serum in the 
presence or absence of 5 μg/mL ssRNA40, using 3 × 106 
cells per well per 100  µL in a 96-well plate. After 48  h 
incubation, the supernatant was harvested, spun down 
at 13,000  rpm for 5  min in a microcentrifuge and run 
on a 4–12  % reducing SDS-PAGE gel (Life Technolo-
gies), and transferred onto a nitrocellulose membrane. 
LILRA3 antibody clone 2E9 (Abnova) was used for 
detection, using Peroxidase Conjugated Stabilized Goat 
Anti-Mouse IgG (H + L) (Pierce) as secondary antibody. 
After stripping the membrane with Restore Western Blot 
Stripping Buffer (Thermo Scientific), IL6 was detected 
using clone MQ2-13A5 (Biolegend) together with Peroxi-
dase Conjugated Stabilized Goat Anti-Rat IgG (H  +  L) 
(Pierce). SuperSignal West Dura Chemiluminescent Sub-
strate (Pierce) was used in conjunction with Versadoc 
MP4000 (Biorad) to visualize the bands.
DNA extraction and LILRA3 deletion genotyping
Genomic DNA was extracted from whole blood using 
Quick-gDNA MiniPrep kit (Zymo Research) according 
to manufacturer’s instructions. LILRA3 deletion genotyp-
ing was done by PCR using reverse primer 5′-GACAG 
CAGATTCTAAAACAGTG-3′ for both genotypes; for-
ward primers 5′-CCCCTGGAGCTCGTGG-3′ for the 
presence genotype and 5′-CATCTCGATCTGCCACTGA 
CAC-3′ for the deletion genotype. PCR for both geno-
types was performed in multiplex using Amplitaq Gold 
DNA Polymerase (Applied Biosystems) using the follow-
ing cycling conditions on the Biometra T3 thermocycler: 
initial denaturation at 95  °C for 20  min, followed by 43 
cycles of denaturation (95  °C for 10  s), annealing and 
elongation (62 °C for 2 min) and a final elongation step of 
62 °C for 10 min. PCR products were analysed on a 1.5 % 
agarose ethidium bromide gel for the presence (1150 bp) 
and deletion (250 bp) genotypes.
Generation of recombinant LILRA3
Mammalian LILRA3 was produced under a Lentivirus 
expression system. Briefly, LILRA3 cDNA was amplified 
by PCR using Phusion High Fidelity DNA Polymerase 
(Thermo Scientific) from total cDNA of PBMC from a 
LILRA3+/− donor using primers (Fwd: 5′-CGGACTAGT 
ATGACCCCCATCCTCACG-3′; Rev: 5′- CGACTAGTT 
CA ATGGTGATGGTGATGGTG CTCACCAGCCTTG 
GAGTC) incorporating SpeI digestion site at both 
ends and His-tag sequence at the 3′ end. The amplified 
LILRA3-His cDNA was cloned into the XbaI site in the 
multiple cloning site of pRRL-CMV-MCS-IRES-GFP 
[51], and the sequence verified by sequencing (MWG 
Operon). The newly generated pRRL-CMV-LILRA3-
His-IRES-GFP was used to transfect HEK-293T cells 
using the LENTI-Smart INT kit (Invivogen) according 
to manufacturer protocol. Virus particles produced were 
concentrated using PEG-it Virus Precipitation Solution 
(System Biosciences) and used to transduce fresh 293T 
cells to generate stable LILRA3-His expressing cell line. 
A stably transduced cell line was also produced using of 
pRRL-CMV-MCS-IRES-GFP for the mock purification 
control. Mammalian LILRA3-His or its equivalent mock 
purification was produced by culturing the transduced 
cells using CELLine AD 1000 bioreactor flasks (INTE-
GRA Biosciences) and purifying the recombinant protein 
using HisPur Cobalt Resin from supernatant adjusted to 
pH 8.2–8.5. Endotoxin level was tested using LAL Chro-
mogenic Endotoxin Quantitation Kit (Pierce) and deter-
mined to be virtually endotoxin free at 5 × 10−6 EU/µg 
protein. LILRA3 purified from Baculovirus expression 
system was produced as described previously [20].
LILRA3 stimulation experiments
For microarray analysis, 106/mL PBMCs were cultured 
for 24 h in the absence or presence of 1 µg/mL baculo-
virus LILRA3 in a 25  cm2 suspension culture flask. The 
cells were pelleted and their total RNA isolated using 
the Qiagen RNeasy Minikit according to the manufac-
turer’s instructions. Microarray and data processing are 
detailed below and deposited in Gene Expression Omni-
bus (accession GSE61356). To confirm the microarray 
data, PBMCs were stimulated overnight with 100, 500 
and 1000  ng/mL of mammalian LILRA3 and analyzed 
for IL-6, IL-1A, IL-1B, IL-10 and LILRA3 expression. 
For changes in B-cell and monocyte expression levels of 
MHC and costimulatory monecules, PBMCs incubated 
for 48  h with 0–1000  ng/mL baculovirus LILRA3 were 
stained with CD14-APC-CY7 (Biolegend), CD19-V450, 
CD3-V500, HLA-ABC-FITC or CD80-FITC, CD86-PE 
(all BD Bioscience) or HLA-DR-PE (Beckman Coulter), 
and analyzed via flow cytometry.
Microarray experiment and data processing
Cy3-labeled cRNA was synthesized using the one color 
Quick Amp Labeling kit (Agilent Technologies) accord-
ing to the manufacturer’s instructions. cRNA fragmenta-
tion and hybridization onto the Whole Human Genome 
Oligo Microarray V2 was carried out as recommended by 
the Agilent One-Color Microarray-Based Gene Expres-
sion Analysis Protocol V5.7. Data were analysed using 
the R software and several packages from BioConductor 
[43] and other sources. Preprocessing steps comprised 
background correction (“normexp”), quantile normali-
sation, probe summarisation, and log2 transformation. 
For the background correction, fitted intensities were 
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calculated by the convolution of normal and exponential 
distributions to observed foreground and background 
intensities [44]. For a robust analysis, median values were 
calculated from replicate samples for each gene. Differen-
tially expressed genes (DEG) were obtained by selecting 
genes with a minimal fold change of two and significant 
changes to untreated controls keeping false-discovery 
rate adjusted p values of 10 % according to the rank prod-
ucts method in order to apply robust statistics for small 
replicate sizes [45, 46]. In order to further functionally 
characterise the selected genes, GOstats for identify-
ing gene ontology terms was applied [47]. A functional 
analysis of the selected gene list was done with SPIA, the 
signaling pathway impact analysis [48]. GSEA served for 
understanding the genome-wide expression of all genes 
[49] via cellHTS2 [50]. The data sets are available under 
GEO accession number GSE61356.
 Statistical Analysis
All statistical analyses were performed using Graphpad 
Prism 5.
Abbreviation LILRA3 leukocyte immunoglobulin like 
receptor A3
Additional files
Additional file 1: Figure S1. Induction of LILRB1 and LILRA1 expression 
by a panel of TLR agonists.LILRA3 expression was measured, using qPCR, 
as fold change to the unstimulated control from PBMCs stimulated for 24 
hours.
Additional file 2: Figure S2. Correlation between LILRA3 expression and 
CD4 and CD8 T-cell and NK-cell counts in HIV-treated patients. One-tailed 
Spearman analysis was used to calculate correlation. Virus loads were 
omitted because almost all treated patients had loads below detection 
limit.Spearman analysis was used to calculate correlation. Non-linear 
regression straight line robust fit was used to calculate the trend lines.
Additional file 3: Figure S3. Gene expression analysis of LILRA3 
stimulated PBMCs. PBMCs from 5 healthy donors treated for 24 hours 
with or without 1 µg/mL LILRA3 was analysed for their gene expression 
using Whole Human Genome Oligo Microarray V2. (A) The top 50 up- and 
downregulated genes based on fold change in their expression levels 
between untreated controls and LILRA3 treatment. (B) and (C) GSEA map 
based on gene ontology for biological processes and KEGG pathway 
mapping respectively. Genes regulated by LILRA3 appears to be enriched 
for, among others, chemotaxis, rheumatoid arthritis and hematopoietic 
cell lineage pathways. Size of the nodes is representative of the number 
of annotated genes within the pathway/term that is regulated, whereas 
the connection thickness is representative of the number of overlapping 
genes between connected nodes.
Additional file 4: Figure S4. IL6 upregulation by purified mammalian 
his-tagged LILRA3, but not by a mock purification. PBMC stimulated for 
24 hours by LILRA3 or an equivalent amount of a mock purification was 
analyzed for IL6 production by qPCR.
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